|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Geyer CE et al. A phase III randomized, open-label, international study comparing lapatinib and capecitabine vs capecitabine in women with refractory advanced metastatic breast cancer (EGF100151). Presentation. Proc ASCO 2006. No abstract available
Martin M et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract
Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659- 72. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
 |
 |
Editor’s Note:
Reality check
Interviews
Marc E Lippman, MD
- Select publications
C Kent Osborne, MD
- Select publications
I Craig Henderson, MD
- Select publications
Charles E Geyer Jr, MD
- Select publications
Frank A Vicini, MD
- Select publications
Miami Beach Cancer Conference Tumor Panel Discussion on Systemic Therapy of Metastatic Disease
- Select publications
 |
 |
 |
 |
 |
